abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2005년 8월 11일

저자:
AIDS Healthcare Foundation

AIDS Drug Prices Still too High for Latin Americans, AIDS Healthcare Foundation

...[In] response to the announcement that 11 Latin American countries have reached an agreement with 26 pharmaceutical companies, including Abbott Laboratories, GlaxoSmithKline, Merck, Bristol-Myers Squibb, Roche and Bayer to reduce the cost of life-saving anti-retroviral (ARV) drugs... "The cost of branded AIDS drugs is so high to begin with that the discounts announced today are not nearly deep enough to provide access to life-saving anti-retroviral medicines to all those who need them in these Latin American countries..." said Michael Weinstein, President, AIDS Healthcare Foundation (AHF)...